AstraZeneca & Daiichi Sankyo Report Interim Analysis Results of Enhertu (trastuzumab deruxtecan) in the P-II Trial (DESTINY-PanTumor02) for HER2-Expressing Advanced Solid Tumors
Shots:
- The interim analysis from an ongoing P-II trial evaluating Enhertu (5.4mg/kg) in 267 patients at multiple sites in Asia, the EU & North America showed clinical & durable responses
- ORR (37.1%) in all IHC expression levels, the greater response was seen in patients with the highest level of HER2 expression IHC 3+ with ORR (61.3%) while CR (5.6%) in the overall trial population; PR (31.5%); SD (46.1%) & DCR (68.2%)
- Patients achieved response (49.6%), m-DoR (11.8mos.) in the overall trial population, 22.1mos. in IHC 3+ expression & the safety profile was consistent with prior trials with no new safety concerns. The P-II trial (DESTINY-CRC02) also showed positive antitumor activity with consistent safety for HER2+ mCRC
Ref: BusinessWire | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
